Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice

American Journal of Pathology

Volumn 181, Issue 1, 2012, Pages 322-333

  Huttinger, Zachary M ^a,b   Milks, Michael W ^a,b   Nickoli, Michael S ^a,b   Aurand, William L ^a,b   Long, Lawrence C ^a,b   Wheeler, Debra G ^a,b   Dwyer, Karen M ^c,d   D'Apice, Anthony J F ^c,d   Robson, Simon C ^e   Cowan, Peter J ^c,d   Gumina, Richard J ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2 RECEPTOR; ADENOSINE B2 RECEPTOR; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE TRIPHOSPHATE; ECTO 5' NUCLEOTIDASE; ECTONUCLEOTIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 1; FERROUS CHLORIDE; FIBRINOGEN RECEPTOR; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; PLATELET FIBRINOGEN RECEPTOR; PURINERGIC RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD CLOTTING; BLOOD VESSEL INJURY; CAROTID ARTERY INJURY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION; HISTOPATHOLOGY; HYDROLYSIS; MOUSE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOGENESIS; VASCULAR RESISTANCE;

ADENOSINE; ANIMALS; ANTIGENS, CD; APYRASE; CAROTID ARTERY THROMBOSIS; CELLS, CULTURED; CHLORIDES; FERRIC COMPOUNDS; MICE; MICE, TRANSGENIC; PLATELET ACTIVATION; PLATELET AGGREGATION; RECEPTORS, PURINERGIC P2; SIGNAL TRANSDUCTION;

EID: 84862697341     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2012.03.024     Document Type: Article

References (74)

1. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001, 104:365-372
2. Massberg S, Schulz C, Gawaz M: Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med 2003, 3:147-162
3. Freedman JE: Molecular regulation of platelet-dependent thrombosis. Circulation 2005, 112:2725-2734
4. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP: Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium. J Exp Med 2003, 198:783-796
5. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH, Robson SC: Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996, 271:33116-33122
6. Koziak K, Sevigny J, Robson SC, Siegel JB, Kaczmarek E: Analysis of CD39/ATP diphosphohydrolase (ATPDase) expression in endothelial cells, platelets and leukocytes. Thromb Haemost 1999, 82:1538-1544
7. Colgan SP, Eltzschig HK, Eckle T, Thompson LF: Physiological roles for ecto-5′-nucleotidase (CD73). Purinergic Signal 2006, 2:351-360
8. Erlinge D, Burnstock G: P2 receptors in cardiovascular regulation and disease. Purinergic Signal 2008, 4:1-20
9. Headrick JP, Peart JN, Reichelt ME, Haseler LJ: Adenosine and its receptors in the heart: regulation, retaliation and adaptation. Biochim Biophys Acta 2011, 1808:1413-1428
10. Cai M, Huttinger ZM, He H, Zhang W, Li F, Goodman LA, Wheeler DG, Druhan LJ, Zweier JL, Dwyer KM, He G, d'Apice AJ, Robson SC, Cowan PJ, Gumina RJ: Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. J Mol Cell Cardiol 2011, 51:927-935
11. Wheeler DG, Joseph ME, Mahamud SD, Aurand WL, Mohler PJ, Pompili VJ, Dwyer KM, Nottle MB, Harrison SJ, d'Apice AJ, Robson SC, Cowan PJ, Gumina RJ: Transgenic swine: expression of human CD39 protects against myocardial injury. J Mol Cell Cardiol 2012, 52:958-961
12. Hatakeyama K, Hao H, Imamura T, Ishikawa T, Shibata Y, Fujimura Y, Eto T, Asada Y: Relation of CD39 to plaque instability and thrombus formation in directional atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol 2005, 95:632-635
13. Dwyer KM, Robson SC, Nandurkar HH, Campbell DJ, Gock H, Murray-Segal LJ, Fisicaro N, Mysore TB, Kaczmarek E, Cowan PJ, d'Apice AJ: Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004, 113:1440-1446
14. Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, Eltzschig HK: Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007, 115:1581-1590
15. Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev 1998, 50:413-492
16. Auchampach JA, Kreckler LM, Wan TC, Maas JE, van der Hoeven D, Gizewski E, Narayanan J, Maas GE: Characterization of the A2B adenosine receptor from mouse, rabbit, and dog. J Pharmacol Exp Ther 2009, 329:2-13
17. Wang X, Xu L: An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res 2005, 115:95-100
18. Hechler B, Freund M, Alame G, Leguay C, Gaertner S, Cazenave JP, Petitou M, Gachet C: The antithrombotic activity of EP224283, a neutralizable dual factor Xa inhibitor/glycoprotein IIbIIIa antagonist. exceeds that of the coadministered parent compounds. J Pharmacol Exp Ther 2011, 338:412-420
19. Henry M, Davidson L, Cohen Z, McDonagh PF, Nolan PE, Ritter LS: Whole blood aggregation, coagulation, and markers of platelet activation in diet-induced diabetic C57BL/6J mice. Diabetes Res Clin Pract 2009, 84:11-18
20. Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, Nieswandt B: Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry 2002, 48:80-86
21. Imai M, Kaczmarek E, Koziak K, Sevigny J, Goepfert C, Guckelberger O, Csizmadia E, Schulte Am Esch J 2nd, Robson SC: Suppression of ATP diphosphohydrolase/CD39 in human vascular endothelial cells. Biochemistry 1999, 38:13473-13479
22. White TA, Pan S, Witt TA, Simari RD: Murine strain differences in hemostasis and thrombosis and tissue factor pathway inhibitor. Thromb Res 2009, 125:84-89
23. Wang L, Miller C, Swarthout RF, Rao M, Mackman N, Taubman MB: Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury. Blood 2009, 113:705-713
24. Owens AP 3rd, Mackman N: Tissue factor and thrombosis: the clot starts here. Thromb Haemost 2010, 104:432-439
25. White TA, Johnson T, Zarzhevsky N, Tom C, Delacroix S, Holroyd EW, Maroney SA, Singh R, Pan S, Fay WP, van Deursen J, Mast AE, Sandhu GS, Simari RD: Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis. Blood 2010, 116:1787-1794
26. Furlan-Freguia C, Marchese P, Gruber AS, Ruggeri ZM, Ruf W: P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest 2011, 121:2932-2944
27. Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch JS 2nd, Imai M, Edelberg JM, Rayburn H, Lech M, Beeler DL, Csizmadia E, Wagner DD, Robson SC, Rosenberg RD: Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 1999, 5:1010-1017
28. Deguchi H, Takeya H, Urano H, Gabazza EC, Zhou H, Suzuki K: Adenosine regulates tissue factor expression on endothelial cells. Thromb Res 1998, 91:57-64
29. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998, 97:251-256
30. Bullough DA, Zhang C, Montag A, Mullane KM, Young MA: Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo. J Clin Invest 1994, 94:1524-1532
31. Kitakaze M, Hori M, Sato H, Takashima S, Inoue M, Kitabatake A, Kamada T: Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs. Circ Res 1991, 69:1402-1408
32. Yang D, Chen H, Koupenova M, Carroll SH, Eliades A, Freedman JE, Toselli P, Ravid K: A new role for the A2b adenosine receptor in regulating platelet function. J Thromb Haemost 2010, 8:817-827
33. Kaul S, Waack BJ, Heistad DD: Asymmetry of vascular responses of perfused rabbit carotid artery to intraluminal and abluminal vasoactive stimuli. J Physiol 1992, 458:223-234
34. Kauffenstein G, Drouin A, Thorin-Trescases N, Bachelard H, Robaye B, D'Orleans-Juste P, Marceau F, Thorin E, Sevigny J: NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse. Cardiovasc Res 2010, 85:204-213
35. Kauffenstein G, Furstenau CR, D'Orleans-Juste P, Sevigny J: The ecto-nucleotidase NTPDase1 differentially regulates P2Y1 and P2Y2 receptor-dependent vasorelaxation. Br J Pharmacol 2010, 159:576-585
36. Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP: Nucleotide receptor signaling in platelets. J Thromb Haemost 2006, 4:2317-2326
37. Offermanns S, Toombs CF, Hu YH, Simon MI: Defective platelet activation in G alpha(q)-deficient mice. Nature 1997, 389:183-186
38. Jin J, Dasari VR, Sistare FD, Kunapuli SP: Distribution of P2Y receptor subtypes on haematopoietic cells. Br J Pharmacol 1998, 123:789-794
39. Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP: Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood 2002, 99:193-198
40. Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH: Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999, 5:1199-1202
41. Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C: Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 1999, 104:1731-1737
42. Hechler B, Lenain N, Marchese P, Vial C, Heim V, Freund M, Cazenave JP, Cattaneo M, Ruggeri ZM, Evans R, Gachet C: A role of the fast ATP-gated P2X1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003, 198:661-667
43. Ohlmann P, Laugwitz KL, Nurnberg B, Spicher K, Schultz G, Cazenave JP, Gachet C: The human platelet ADP receptor activates Gi2 proteins. Biochem J 1995, 312:775-779
44. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, Lachowicz JE, Zhang FL, Gustafson E, Monsma FJ Jr, Wiekowski MT, Abbondanzo SJ, Cook DN, Bayne ML, Lira SA, Chintala MS: Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001, 107:1591-1598
45. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, Koller B, Phillips DR, Conley PB: P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003, 112:398-406
46. Lecka J, Rana MS, Sevigny J: Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation. Br J Pharmacol 2010, 161:1150-1160
47. Oury C, Kuijpers MJ, Toth-Zsamboki E, Bonnefoy A, Danloy S, Vreys I, Feijge MA, De Vos R, Vermylen J, Heemskerk JW, Hoylaerts MF: Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype. Blood 2003, 101:3969-3976
48. Goto S, Tamura N, Ishida H, Ruggeri ZM: Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5=-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 2006, 47:155-162
49. Bourgain RH, Vermarien H, Andries R, Vereecke F, Jacqueloot J, Rennies J, Blockeel E, Six F: A standardized 'in vivo' model for the study of experimental arterial thrombosis: description of a method. Adv Exp Med Biol 1984, 180:635-649
50. Born GV: Adenosine diphosphate as a mediator of platelet aggregation in vivo. Adv Exp Med Biol 1985, 192:399-409
51. Cattaneo M, Canciani MT, Lecchi A, Kinlough-Rathbone RL, Packham MA, Mannucci PM, Mustard JF: Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990, 75:1081-1086
52. Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C: A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999, 94:4156-4165
53. Hart ML, Kohler D, Eckle T, Kloor D, Stahl GL, Eltzschig HK: Direct treatment of mouse or human blood with soluble 5′-nucleotidase inhibits platelet aggregation. Arterioscler Thromb Vasc Biol 2008, 28:1477-1483
54. Klabunde RE: Dipyridamole inhibition of adenosine metabolism in human blood. Eur J Pharmacol 1983, 93:21-26
55. Dawicki DD, Agarwal KC, Parks RE Jr: Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine. Biochem Pharmacol 1985, 34:3965-3972
56. Iyu D, Glenn JR, White AE, Fox SC, Heptinstall S: Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arterioscler Thromb Vasc Biol 2011, 31:416-422
57. Koszalka P, Ozuyaman B, Huo Y, Zernecke A, Flogel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sevigny J, Gear A, Weber AA, Molojavyi A, Ding Z, Weber C, Ley K, Zimmermann H, Godecke A, Schrader J: Targeted disruption of cd73/ecto-5′-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 2004, 95:814-821
58. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 1997, 388:674-678
59. Amisten S, Braun OO, Bengtsson A, Erlinge D: Gene expression profiling for the identification of G-protein coupled receptors in human platelets. Thromb Res 2008, 122:47-57
60. Doni MG, Deana R, Bertoncello S, Zoccarato F, Alexandre A: Forskolin and prostacyclin inhibit fluoride induced platelet activation and protein kinase C dependent responses. Biochem Biophys Res Commun 1988, 156:1316-1323
61. Cooper JA, Hill SJ, Alexander SP, Rubin PC, Horn EH: Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets. Br J Clin Pharmacol 1995, 40:43-50
62. Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I: Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002, 105:2166-2171
63. Glenn JR, White AE, Johnson AJ, Fox SC, Myers B, Heptinstall S: Raised levels of CD39 in leucocytosis result in marked inhibition of ADP-induced platelet aggregation via rapid ADP hydrolysis. Platelets 2008, 19:59-69
64. Friedman DJ, Kunzli BM, A-Rahim YI, Sevigny J, Berberat PO, Enjyoji K, Csizmadia E, Friess H, Robson SC: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc Natl Acad Sci U S A 2009, 106:16788-16793
65. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG: ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006, 314:1792-1795
66. Linden J: New insights into the regulation of inflammation by adenosine. J Clin Invest 2006, 116:1835-1837
67. Hasko G, Linden J, Cronstein B, Pacher P: Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008, 7:759-770
68. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, Junger WG: Ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem 2008, 283:28480-28486
69. Chen Y, Yao Y, Sumi Y, Li A, To UK, Elkhal A, Inoue Y, Woehrle T, Zhang Q, Hauser C, Junger WG: Purinergic signaling: a fundamental mechanism in neutrophil activation. Sci Signal 2010, 3:ra45
70. Kronlage M, Song J, Sorokin L, Isfort K, Schwerdtle T, Leipziger J, Robaye B, Conley PB, Kim H-C, Sargin S, Schon P, Schwab A, Hanley PJ: Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal 2010, 3:ra55
71. Lévesque SA, Kukulski F, Enjyoji K, Robson SC, Sévigny J: NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur J Immunol 2010, 40:1473-1485
72. Bach RR: Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006, 26:456-461
73. Straub A, Krajewski S, Hohmann JD, Westein E, Jia F, Bassler N, Selan C, Kurz J, Wendel HP, Dezfouli S, Yuan Y, Nandurkar H, Jackson S, Hickey MJ, Peter K: Evidence of platelet activation at medically used hypothermia and mechanistic data indicating ADP as a key mediator and therapeutic target. Arterioscler Thromb Vasc Biol 2011, 31:1607-1616
74. Schwarz M, Meade G, Stoll P, Ylanne J, Bassler N, Chen YC, Hagemeyer CE, Ahrens I, Moran N, Kenny D, Fitzgerald D, Bode C, Peter K: Conformation-specific blockade of the integrin GPIIb/IIIa. Circ Res 2006, 99:25-33